ELEPHAS BIOSCIENCES RAISES $40M TO ACCELERATE COMMERCIALIZATION OF ITS LIVE TUMOR PROFILING PLATFORM

Elephas Biosciences raised $40 million (Series B‑2) from existing investors including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital, and others. The capital will fund launch and commercialization of the Elephas Live platform as a laboratory developed test in 2026. The company profiles ex vivo live tumor biopsies to predict immunotherapy response by preserving the native tumor microenvironment and addressing tumor heterogeneity.